230
Views
4
CrossRef citations to date
0
Altmetric
Articles

Potential years of life and productivity loss due to malignant mesothelioma in Turkey

, &

References

  • Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occup Environ Med. 2014;18(2):82–88. doi:10.4103/0019-5278.146897.
  • Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17(4):260–271. doi:10.1136/oem.17.4.260.
  • McDonald JC. Epidemiology of malignant mesothelioma–an outline. Ann Occup Hyg. 2010;54:851–857. doi:10.1093/annhyg/meq076.
  • McDonald C, ed. Epidemiology of Work Related Diseases. London: BMJ Books; 2000.
  • Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2007;369(9564):844–849. doi:10.1016/S0140-6736(07)60412-7.
  • Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1:491–496. doi:10.3978/j.issn.2225-319X.2012.11.04.
  • Park EK, Takahashi K, Jiang Y, et al. Elimination of asbestos use and asbestos-related diseases: An unfinished story. Cancer Sci. 2012;103(10):1751–1755. doi:10.1111/j.1349-7006.2012.02366.
  • Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med. 1999;56(8):505–513. doi:10.1136/oem.56.8.505.
  • Metintas S, Ak G, Metintas M. A review of the cohorts with environmental and occupational mineral fiber exposure. Arch Environ Occup Health. 2019;74(1–2):76–84. doi:10.1080/19338244.2018.1467873.
  • Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos. Chest. 2002;122(6):2224–2229.
  • Metintaş S, Batırel HF, Bayram H, et al. Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program. IJERPH. 2017;14(11):E1293. doi:10.3390/ijerph14111293.
  • Kim JL, Cho KH, Park EC, Cho WH. A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev. 2014;15(1):433–439. doi:10.7314/APJCP.2014.15.1.433.
  • Khorasani S, Rezaei S, Rashidian H, Daroudi R. Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran. Asian Pac J Cancer Prev. 2015;16(5):1845–1850. doi:10.7314/APJCP.2015.16.5.1845.
  • Hanly PA, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer. 2014;14(1):224. doi:10.1186/1471-2407-14-224.
  • The Global Economy and Turkey: an OECD perspective. Organisation for Economic Co-operation and Development. https://www.oecd.org/turkey/theglobaleconomyandturkeyanoecdperspective.htm. Accessed March 20, 2019.
  • Statistics on unemployment and supplementary measures of labour underutilization. International Labour Organization. https://ilostat.ilo.org/topics/unemployment-and-labour-underutilization/. Accessed March 20, 2019.
  • Murray C. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Org. 1994;72:429–445.
  • Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136(4):E136–E145. doi:10.1002/ijc.29105.
  • Steenland K, Armstrong B. An overview of methods for calculating the burden of disease due to specific risk factors. Epidemiology. 2006;17:512–519. doi:10.1097/01.ede.0000229155.05644.43.
  • Ortiz-Ortiz KJ, Pérez-Irizarry J, Marín-Centeno H, et al. Productivity loss in Puerto Rico's labor market due to cancer mortality. P R Health Sci J. 2010;29:241–249.
  • Najafi F, Karami-Matin B, Rezaei S, et al. Productivity costs and years of potential life lost associated with five leading causes of death: evidence from Iran (2006-2010). Med J Islam Repub Iran. 2016;30:412. eCollection 2016.
  • Bang KM, Mazurek JM, Wood JM, Hendricks SA. Diseases attributable to asbestos exposure: years of potential life lost, United States, 1999–2010. Am J Ind Med. 2014;57(1):38–48. doi:10.1002/ajim.22261.
  • Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44–58. doi:10.1002/jcp.22724.
  • Brustugun OT, Møller B, Helland A. Years of life lost as a measure of cancer burden on a national level. Br J Cancer. 2014;111(5):1014–1020. doi:10.1038/bjc.2014.364.
  • Rouse C, Gittleman H, Ostrom QT, et al. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol. 2016;18(1):70–77. doi:10.1093/neuonc/nov249.
  • Metintas S, Ak G, Yilmaz S, et al. Validity and reliability of asbestos knowledge and awareness questionnaire for environmental asbestos exposure in rural areas. Eurasian J Pulmonol. 2017;19(1):34–40. doi:10.5152/ejp.2016.57441.
  • Metintas S, Ak G, Bogar F, et al. Asbestos knowledge and awareness level in central part of Anatolia. Int J Occup Environ Health. 2017;23(3):243–249. doi:10.1080/10773525.2018.1470789.
  • Şenyiğit A, Babayiğit C, Gökirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration. 2000;67(6):610–614. doi:10.1159/000056289.
  • Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden––and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241–245. doi:10.1038/sj.bjc.660232.
  • Ak G, Metintas S, Kose T, et al. The relationship between treatment cost and prognosis of malignant pleural mesothelioma in Turkey. Eurasian J Pulmonol. 2019;21:50–56. doi:10.4103/ejop.ejop_41_18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.